Researchers Use New Method to Control Bleeding in Hemophilia
Posted on: Thursday, 13 November 2008, 15:00 CST
MILWAUKEE, Nov. 13 /PRNewswire/ -- Investigators at Children's Research Institute, BloodCenter of Wisconsin's Blood Research Institute and the Medical College of Wisconsin have discovered a new way to help the blood clot by having the missing clotting factor packaged in the patient's own platelets. In the October 2008 edition of Blood, investigators describe how a gene-modified bone marrow transplant can be used to initiate clotting in hemophilia. This type of approach may work in the 30 to 35 percent of hemophilia patients that have developed inhibitory antibodies against the missing clotting protein.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081113/AQTH090)
The bone marrow is removed from the patient and stem cells are treated with Factor VIII, a clotting factor, which is placed in the platelets. The marrow is given back to the patient, who then retains the essential clotting mechanisms to stop bleeding that otherwise would lead to complications.
For people suffering from hemophilia, this research means the potential relief of a constant, burdening disease. People who have hemophilia previously had to be treated every time they bled. Currently, they can receive treatments three times a week, but these are very costly and time consuming. The results from this study provide hope that people with hemophilia could potentially lead a disease-free life.
The scientific community once believed that hemophilia would be treated successfully by gene therapy. Research then showed that gene therapy typically resulted in the patient not retaining a substantial amount of clotting factor, which is integral in preventing serious bleeding.
This research was a collaborative effort that included investigators Qizen Shi, PhD, MD; David A. Wilcox, PhD; and Robert Montgomery, MD.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20081113/AQTH090AP Archive: http://photoarchive.ap.org/AP PhotoExpress Network: PRN8PRN Photo Desk, photodesk@prnewswire.com
Children's Research Institute
CONTACT: Erin Hareng, +1-414-266-5420, toll-free, 1-866-416-1511, forChildren's Research Institute
Web site: http://www.chw.org/
Source: PRNewswire
Related Articles
- New Research Suggests Platelet 'Stickiness' May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease
- Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
- Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
- Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
- Sanofi Drug Reduces Clot Risk in Stroke Patients
- Journal of Clinical Oncology Publishes Study of Colorectal Liver Metastases Patients Treated With Combination Radiofrequency Ablation and Chemotherapy Suggesting Survival Benefit
- Scientific Research Finds Gut Bacterium Capable of Changing Genes
- Sex Disparities in Treatment of Cardiac Risk Factors in Patients With Type 2 Diabetes
- 2',5'-Oligoadenylate Synthetase Activity Analysis and Human Papilloma Virus Typing As Prognostic Factors in Patients With Recurrent Respiratory Papillomatosis
- New Two-Year Data Show That Most Rheumatoid Arthritis Patients Treated With ENBREL Plus Methotrexate Had No Progression of Joint Damage
 |
 |
User Comments (0)
RSS Feeds